These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Investigation of tumour supressor protein p53 in renal cell carcinoma patients.
    Author: Hodorova I, Solar P, Mihalik J, Vecanova J, Adamkov M, Rybarova S.
    Journal: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):44-9. PubMed ID: 23073516.
    Abstract:
    BACKGROUND: Investigation of p53 immunoreactivity in formalin-fixed paraffin-embedded tissues of normal renal tissue and renal cell carcinoma with respect to histopathologic subtype and nuclear grade of RCC. METHODS: 42 tissue sections of RCC and 5 samples of normal renal tissue were stained for p53 expression using immunohistochemical assay. The results were analyzed in relation to nuclear grade and histopathologic subtype. RESULTS: In total, p53 expression was found to be 4 to 5 times higher (30.8%) in other types of RCC than in the clear-cell type of RCC (6.9%). Further, there was no statistically significant difference in p53 overexpression among the histopathologic subtypes (P>0.05, P=0.063). No association was found between the expression of p53 and nuclear grade (P>0.05, P=0.17). Interestingly, our study also showed weak cytoplasmic positivity in renal tubular epithelium. CONCLUSION: Our findings suggest that p53 might play an important role in tumour development or progression and it might be used as a new predictor and therapeutic target for RCC.
    [Abstract] [Full Text] [Related] [New Search]